ライフサイエンスコーパス: bivalent

1 able loss in k-fibres, or tension across the bivalent.

2 domains referred to as the long arms of the bivalents.

3 tion was enriched at CpG islands marked with bivalent activating and repressing histone modifications

4 components (TOG and RNA) are modulated by a bivalent adaptor molecule (hnRNP A2).

5 loaddition using bis(TMS)butadiyne and other bivalent alkynes.

6 ith different biological functions; (iii) HC bivalent and active promoters were CpG rich while H3K27m

7 Bivalent and biparatopic nanobodies were generated, resp

8 into the structure-activity relationships of bivalent and linker-attached compounds in mAChRs.

9 pared with the single-domain version of FC5; bivalent and monovalent FC5 fusions with Fc exhibited si

10 The interference caused by bivalent and monovalent OPV formulations, which will be

11 Bivalent and quadrivalent HPV vaccines protect against 6

12 The two licensed bivalent and quadrivalent human papillomavirus (HPV) L1

13 First generation bivalent and quadrivalent human papillomavirus (HPV) vac

14 shown to be cost-effective compared with the bivalent and quadrivalent vaccines at any coverage despi

15 le platform that can be labeled with various bivalent and trivalent radiometals without comprising th

16 se in sister kinetochore separation, rotated bivalents and merotelic attachments.

17 Here, we want to extend the concept to bivalent antagonism.

18 Birinapant (1) is a second-generation bivalent antagonist of IAP proteins that is currently un

19 re caused by the cross-linking of virions by bivalent antibodies into aggregates with prominent side-

20 tween rod-like virus particles (virions) and bivalent antibodies.

21 nts did not show any effect, indicating that bivalent antibody binding is required to reduce fimbrial

22 saturating antibody concentrations, and that bivalent antibody binding may be more common than previo

23 n dimers created through genetic fusion to a bivalent antibody domain exhibited only modest improveme

24 In this study, small and bivalent antibody fragments, including anti-prostate-spe

25 In this work, we hypothesize that the bivalent antigen-binding fragment regions of immunoglobu

26 Such a bivalent approach may provide a mechanism for fine tunin

27 RNA-based aptamer-siRNA chimera, in which a bivalent aptamer specifically binds prostate-specific me

28 Our results support that the bivalent aptamer-driven delivery of two siRNAs could be

29 as been made, the homologues of a 4-mum-long bivalent begin to separate.

30 eries showed enhanced potency as a result of bivalent binding and a clear correlation between BRD4 ac

31 e 53BP1-dependent repair through competitive bivalent binding and modification of chromatin.

32 Bivalent binding may be essential for a DDAb to cause th

33 A bivalent binding mechanism is able to describe the conce

34 The bivalent binding mode might be explained by a two-step c

35 able to differentiate between the mono- and bivalent binding modes during individual antibody-antige

36 A similar bivalent binding strategy may underlie the collagen-FN i

37 ntly because HIV's low spike density impedes bivalent binding through inter-spike crosslinking, and t

38 gineered antibody-based molecules capable of bivalent binding through intra-spike crosslinking.

39 sslinking, and the spike structure prohibits bivalent binding through intra-spike crosslinking.

40 Fab domain flexibility necessary for hetero-bivalent binding to the Env trimer while retaining the f

41 lored the possibility of using antibodies as bivalent biomolecular substrates for the templated assem

42 However, bivalent biorientation remained uncoupled from APC activ

43 We show that a bivalent biparatopic antibody targeting two non-overlapp

44 onovalent bispecific variants, but not their bivalent bispecific counterparts, mediated a greater deg

45 Specifically, a series of monovalent and bivalent bispecific IgGs composed of the anti-HER2 trast

46 e April 2016 switch from trivalent (tOPV) to bivalent (bOPV) oral polio vaccine at the national-level

47 he discovery and optimization of a series of bivalent bromodomain and extraterminal inhibitors.

48 titoxins to neutralize the toxicity of known bivalent C. botulinum strains Ab, Ba, Af, and Bf also fa

49 iently as a reference mouse mAb and that the bivalent CA4910 nanobody behaves as an efficient antagon

50 Engineering of a bivalent CA4910 nanobody resulted in a relatively modest

51 Bivalent cation (64)Cu(2+) and trivalent cation (44)Sc(3

52 Unlike bivalent CD33 antibodies, AMG 330 did not reduce surface

53 In this study, we constructed a bivalent chimeric virus-like particle (VLP) presenting t

54 that the conjunction of hypermethylation of bivalent chromatin and up-regulation of the correspondin

55 drives lymphomagenesis through formation of bivalent chromatin domains at critical germinal center (

56 Experimental evidence indicates that bivalent chromatin domains, i.e., genome regions that ar

57 KSHV episomes are known to possess bivalent chromatin domains.

58 on, demonstrating the unexpected presence of bivalent chromatin in both cultured and uncultured cells

59 Thus, we reason that the disturbance of bivalent chromatin may be intimately linked to tumorigen

60 n shown to exhibit partial recapitulation of bivalent chromatin modifications that are lost along wit

61 velopmental regulators have a characteristic bivalent chromatin signature marked by simultaneous pres

62 Gadd45b)] where it functions to maintain the bivalent chromatin state by preventing excessive polycom

63 drives iNKT cell differentiation possesses a bivalent chromatin state characterized by the simultaneo

64 Interestingly, the H3K4me3/H3K27me3 bivalent chromatin structure observed in progenitors per

65 al lytic switch gene, Rta, is organized into bivalent chromatin, similar to cellular developmental sw

66 ncer samples solely from hypermethylation of bivalent chromatin.

67 bryonic stem cells (ESCs) some CGIs adopt a 'bivalent' chromatin state bearing simultaneous 'active'

68 Poised (bivalent) chromatin is defined by the simultaneous prese

69 8, Smc1beta is not required for establishing bivalent cohesion [11, 12].

70 o Smc3/Smc1alpha or Smc3/Smc1beta, maintains bivalent cohesion in mammalian meiosis [2-6].

71 red a large and random formatting library of bivalent (combinations of two identical) and biparatopic

72 e propose that identification of PRC1-Br140 "bivalent complexes" in fly embryos supports and extends

73 gradation of non-native neo-substrates using bivalent compounds known as PROTACs (for 'proteolysis-ta

74 and/or N-5 of 1 and the capacity of the new bivalent compounds to selectively activate G-proteins ve

75 The stability of the bivalent configuration against the monovalent one is con

76 dies were superior over their monovalent and bivalent counterparts in terms of potency and efficacy.

77 In addition, a binding study with the bivalent cyclic and linear polypeptides reveals that a c

78 ysine 191 in D2 with sites on LRP1 to form a bivalent D1D2-LRP1 complex.

79 Addition of bivalent D2 receptor ligands also resulted in a large in

80 study cholesteric shells with monovalent and bivalent defect configurations.

81 work for structure-activity relationships of bivalent degraders are anticipated to have wide future a

82 nteractions of the Influenza A virus HA with bivalent displays of the natural sialyl-LacNAc ligand.

83 In vivo, changes of the bivalent domain accompanied Shh-activated cerebellar pro

84 t sites marked with H3K4me3 to establish the bivalent domain.

85 lysis reveals that these de novo synthesized bivalent domains are largely associated with a subset of

86 s alteration is sufficient in making de novo bivalent domains at these loci.

87 lishment and maintenance of H3K4me3/H3K27me3 bivalent domains underlying methylated DNA CpG islands (

88 s results in an apparent loss of H3K27me3 at bivalent domains, which are associated with a particular

89 frequently co-occupy gene promoters, forming bivalent domains.

90 nd reveals unique insight into the nature of bivalent domains.

91 l for the formation of segregation-competent bivalents during meiosis I, and findings suggest that ag

92 ions were synthesized by the reaction of the bivalent electrophile thiabicyclo[3.3.1]nonane dinitrate

93 27me3-associated inactive states and poised (bivalent) enhancer states.

94 This bivalent epigenetic control of oncofetal gene expression

95 We examined the poised (H3K4me3/H3K27me3 bivalent) epigenetic state in male germ cells from five

96 A CVA16 vaccine or bivalent EV71/CVA16 vaccine is therefore urgently needed

97 main pure antagonists even when formatted as bivalent Fc-fusion proteins, making this an attractive t

98 of an ALVAC-SIV vaccine boosted either with bivalent FLSC proteins or with monomeric gp120 in alum.

99 of distinct sets of regulators distinguished bivalent from active promoters.

100 In vitro studies demonstrated that the bivalent fusion of FC5 with Fc increased the rate of tra

101 I with complementary sites on LRP1 to form a bivalent fVIII.LRP1 complex.

102 eradicates PRC2 targeting on the majority of bivalent gene promoters and leads to transcriptional de-

103 4 methylation/demethylation are recruited to bivalent gene promoters in a cell cycle-dependent fashio

104 omb within minutes, leading to activation of bivalent gene transcription in mouse embryonic stem cell

105 gely dispensable for continued repression of bivalent genes and de novo silencing in 2i.

106 not Mll2 functions as the H3K4 methylase on bivalent genes and is required for their expression, sup

107 ion of numerous retinoic acid (RA)-inducible bivalent genes during the RA-driven differentiation of m

108 Interestingly, bivalent genes enriched with H3K4me3 exclusively during

109 Analysis of a representative set of bivalent genes revealed that chromatin modifiers involve

110 g nucleosome stability, at polycomb-enriched bivalent genes the same remodellers act in an opposite m

111 In human embryonic stem cells (hESCs), bivalent genes with both activating (H3K4me3) and repres

112 tion to implementing H3K4me3 at promoters of bivalent genes, Mll2 (KMT2B)/COMPASS can also implement

113 on and not, as expected, at developmental or bivalent genes.

114 mESCs, is enriched at many mESC-specific and bivalent genes.

115 llar vesicles in water (CAC < 0.25 muM), and bivalent guests 4/5 populating the cavities of such bola

116 Bivalent H3K4me3 and H3K27me3 chromatin domains in embry

117 A new study tracks the distribution of bivalent H3K4me3/H3K27me3 chromatin in male germ cells o

118 complex with JNK3 (4X21) reveals an unusual bivalent halogen/chalcogen bond donated by the ligand an

119 e in vitro and in vivo antitumor efficacy as bivalent Herceptin/rGel conjugate.

120 y histone H3K4me1, histone H3K27me3, and the bivalent histone mark H3K27me3 + H3K4me3 in human CD34+

121 found that ZIC2 degradation by K-Rta shifts bivalent histone marks to a more active configuration, l

122 Bivalent histone modifications are defined as repressive

123 tently, Tol2 insertions were associated with bivalent histone modifications characteristic of silent

124 ly, depletion of ZIC2 shifted the balance of bivalent histone modifications toward more active forms

125 ate that developmental gene loci, which have bivalent histone modifications, tend to colocalize in PS

126 e in embryonic stem cells but premarked with bivalent histone modifications; one allele was silenced

127 X-mediated resolution and activation of many bivalent Hox genes during mouse ESC differentiation were

128 efore and 28 days following a single dose of bivalent HPV vaccine (2vHPV; Cervarix, GlaxoSmithKline).

129 s) or 3 doses (at 0, 1, and 6 months) of the bivalent HPV vaccine were identified in the vaccination

130 r to explain partial cross-protection by the bivalent HPV vaccine.

131 4 years after vaccination suggests that the bivalent HPV-16/18 vaccine has protective efficacy in me

132 A bivalent HSA conjugate was also prepared in a site-speci

133 demonstrated partial cross-protection by the bivalent human papillomavirus (HPV) vaccine, which targe

134 or routine vaccination with the prophylactic bivalent human papillomavirus (HPV) vaccine.

135 is recommended for both the quadrivalent and bivalent human papillomavirus (HPV) vaccines.

136 of Ab to neutralize parasites; and 4) intact bivalent IgG contributes to but is not necessary for par

137 ecombinant gelonin (rGel) to the activity of bivalent IgG-containing immunoconjugates.

138 gaging HER2 and IL13Ralpha2 in an augmented, bivalent immune synapse that enhances T cell functionali

139 d on a cyclic defensin protein, as well as a bivalent immunogen with two copies of the epitope on the

140 modification signature of genes that remain bivalent in differentiated cells resolves into a cell cy

141 Over 85% of H3K27me3 marked promoters were bivalent in human and mouse ES cells.

142 tective efficacy of FILORAB1, a recombinant, bivalent, inactivated rabies virus-based EBOV vaccine, i

143 nity is increased 10 000- to 100 000-fold by bivalent interaction between antibody and its target.

144 Formation of the bivalent interaction between the Notch intracellular dom

145 urface plasmon resonance analysis revealed a bivalent interaction mode for Pex5p and Pcs60p.

146 tion of two drug-binding pockets to create a bivalent interaction that allows inhibition of these res

147 The 111-residue RAM region mediates bivalent interactions of NICD with the transcription fac

148 These bivalent interactions prime retromer to capture integral

149 ecruited to DNA double-strand breaks through bivalent interactions with both histone and DNA componen

150 gomerization and tandem-BRCT domain-mediated bivalent interactions with p53 and the ubiquitin-specifi

151 We propose that bivalent interactions with the double stranded RNA bindi

152 and immunogenic for further development as a bivalent intranasal pediatric vaccine.

153 A bivalent intranasal RSV/HPIV3 vaccine candidate consisti

154 usly evaluated in seronegative children as a bivalent intranasal RSV/HPIV3 vaccine, and it was well t

155 This bivalent Lewis acidity leads to an especially high affin

156 84, the prototype of our previously reported bivalent ligand TTR 'superstabiliser' family, is notably

157 , this is the first report of a melanocortin bivalent ligand's in vivo physiological effects.

158 lved in such cross-talk, we have synthesized bivalent ligands (MCC series) that contain mu opioid ago

159 A functional switch is observed for the bivalent ligands 3b,c inhibiting cAMP formation in cells

160 We report here bivalent ligands consisting of two identical oxytocin-mi

161 l synthesis and biological investigations of bivalent ligands for dopamine D2 receptor/neurotensin NT

162 The development of bivalent ligands has attracted interest as a way to pote

163 Bivalent ligands of G protein-coupled receptors have bee

164 The newly discovered oxytocin bivalent ligands represent a powerful tool for targeting

165 Moreover, the newly synthesized bivalent ligands show a strong, predominantly NTS1R-medi

166 The bivalent ligands show binding affinity in the picomolar

167 Unexpectedly, different bivalent ligands showed preferences for particular melan

168 ent behavior follows from the binding of the bivalent ligands to dimeric receptors based on a TMH1-TM

169 study focused on the design and synthesis of bivalent ligands to target melanocortin receptor homodim

170 cope of the method, the assembly of a set of bivalent ligands, which integrate members of the epiderm

171 roviding evidence of the discrete effects of bivalent ligands.

172 Then, a kinetic model based on a bivalent ligation suggested that the reaction between th

173 ctor expressing RSV F protein is a candidate bivalent live vaccine against HPIV3 and RSV.

174 pancy of PRC1 and a Br140 ortholog, BRD1, at bivalent loci in human embryonic stem (ES) cells.

175 position of histone H3K27me3 at a subset of 'bivalent' loci but in NPC it is needed at 'bivalent' loc

176 'bivalent' loci but in NPC it is needed at 'bivalent' loci for both the proper maintenance and the a

177 c polypeptide was also accomplished to yield bivalent M6P-glycopeptides.

178 NA PolII, H3K27ac, and H3K36me3, but not the bivalent mark H3K4me2.

179 Groups of tissue-specific genes that carry bivalent marks are repressed, despite the presence of pr

180 These bivalent modifications are maintained at most somatic pr

181 e show an alternative and previously unknown bivalent modified histone signature in lineage-committed

182 la enterica serovar Typhi strain to create a bivalent mucosal plague vaccine that produces both the p

183 length resulted in the identification of two bivalent noncompetitive D3R-selective antagonists, 18a a

184 We assessed 2 bivalent norovirus virus-like particle (VLP) vaccine can

185 Bivalent norovirus VLP vaccine reduced norovirus-related

186 We identified definitively bivalent nucleosomes with concomitant repressive and act

187 s to assess the efficacy of two schedules of bivalent OPV (bOPV) and IPV and challenge with monovalen

188 hronized switch from trivalent OPV (tOPV) to bivalent OPV (bOPV) as recommended by the Strategic Advi

189 e global switch from trivalent OPV (tOPV) to bivalent OPV (bOPV) can inform the eventual full global

190 bal replacement of trivalent OPV (tOPV) with bivalent OPV (bOPV) during April - May 2016, a transitio

191 and to "switch" from trivalent OPV (tOPV) to bivalent OPV (bOPV) in all countries still using OPV in

192 OPV1-4 weeks) between doses, or two doses of bivalent OPV (bOPV) with an interval of 4 weeks between

193 s after a challenge dose of serotype 1 and 3 bivalent OPV (bOPV).

194 containing types 1, 2, and 3 poliovirus) to bivalent OPV (bOPV; containing types 1 and 3 poliovirus)

195 PV (tOPV; types 1, 2, and 3 polioviruses) to bivalent OPV (bOPV; types 1 and 3 polioviruses) during a

196 (containing types 1, 2, and 3 poliovirus) to bivalent OPV (containing types 1 and 3 poliovirus) calle

197 icy decision to switch from trivalent OPV to bivalent OPV and to introduce 1 dose of inactivated poli

198 as poliovirus shedding in stool 7 days after bivalent OPV challenge at 11 months.

199 or use of inactivated poliovirus vaccine and bivalent OPV in routine immunization.

200 receive 3 doses of monovalent OPV type 1 or bivalent OPV types 1 and 3 at either 6, 8, and 10 or 6,

201 was used initially, followed subsequently by bivalent OPV) targeting various age groups, including ch

202 d between inactivated poliovirus vaccine and bivalent OPV.

203 t type 1 oral poliovirus vaccine (mOPV1) and bivalent OPV1 and 3 (bOPV) vaccines through campaigns is

204 d, we develop a fitting-free, minimal model: bivalent or multivalent red and green 'transcription fac

205 Coadministration of monovalent, bivalent, or trivalent OPV seems to lower RV1 immunogeni

206 We evaluated immune responses following bivalent oral cholera vaccination (Shanchol [Shantha Bio

207 replacing trivalent oral polio vaccine with bivalent oral polio vaccine ("the switch").

208 from trivalent oral polio vaccine (tOPV) to bivalent oral polio vaccine (bOPV) ("the switch") presen

209 from trivalent oral polio vaccine (tOPV) to bivalent oral polio vaccine (bOPV) has constituted an ef

210 in relation to the switch from trivalent to bivalent oral polio vaccine (OPV) in the 11 countries of

211 campaigns with inactivated polio vaccine and bivalent oral polio vaccine on stopping transmission.

212 Bivalent oral poliovirus vaccine (bOPV; types 1 and 3) i

213 (Ty21a) by using it as a vector to develop a bivalent oral vaccine to protect against S. sonnei shige

214 s composed of two IDP chains cross-linked by bivalent partner proteins form scaffolds for assembly of

215 Focusing on the bivalent PAX6 locus, we find that increased DNMT3B bindi

216 enetic approach, we demonstrate utility of a bivalent pharmacophore with dual activity as a mu/delta

217 Bivalent (poised or paused) chromatin comprises activati

218 viruses in Vietnam, the vaccine efficacy of bivalent poultry vaccine formulations should be tested i

219 the de-repression of selected, predominantly bivalent PRC2 target genes that are dominated by self-re

220 mentation for thermofluorimetric analysis of bivalent probe (TFAB) assemblies, allowing protein level

221 As protein-bound bivalent probes are thermodynamically more stable than u

222 Moreover, H3K27me3 levels and the number of bivalent promoter genes were reduced in BAF250a KO ES ce

223 bryonic stem cells (hESCs) exhibit prominent bivalent promoter hypermethylation without an overall co

224 late known patterns such as super-enhancers, bivalent promoters and Polycomb repressed regions, and i

225 elf-renewing tissues show fewer and distinct bivalent promoters compared to ESCs.

226 ses, we conclude that TET proteins safeguard bivalent promoters from de novo methylation to ensure ro

227 Bivalent promoters gradually increase, while repressive

228 Bivalent promoters in embryonic stem cells (ESCs) carry

229 H3K27me3, which is largely absent at bivalent promoters in ground-state 2i mESCs, is necessar

230 ns between a small subset of H3K27me3 marked bivalent promoters involving the Hox clusters in serum-g

231 Typically, DNA at bivalent promoters is only lowly methylated in normal ce

232 We found that (i) HC bivalent promoters were enriched for developmental facto

233 cription factor perturbation; (ii) murine HC bivalent promoters were occupied by both polycomb repres

234 induced in GC B cells, binds to H3K27me3 at bivalent promoters, and is required for stable associati

235 ES cells, and predicted high-confidence (HC) bivalent promoters.

236 sequence motif was specifically enriched in bivalent promoters.

237 pposition of Polycomb-mediated repression at bivalent promoters.

238 expressing RSV fusion (F) protein to confer bivalent protection against RSV and HPIV3.

239 ay play a critical role in the resolution of bivalent protein complexes during development.

240 platform was demonstrated by detecting five bivalent proteins (four antibodies and the chemokine pla

241 rs against rabies virus, illustrating that a bivalent rabies virus-based vaccine against CDV induces

242 Optimal bivalent reagents exhibited up to 2.5 orders of magnitud

243 was to evaluate the protective efficacy of a bivalent, recombinant vesicular stomatitis virus vaccine

244 se data are consistent with a model in which bivalent recruitment of a GADS/SLP-76 complex is require

245 Furthermore, our findings also show that bivalent regions have fewer nucleosome-depleted regions

246 Polyamines act as bivalent regulators of cellular function and are involve

247 ents who had received three doses of 120 mug bivalent rLP2086 (the optimum dose level identified in s

248 11, 170 participants who received 120 mug of bivalent rLP2086 and 80 participants who received placeb

249 ted in seven (4%) of 170 participants in the bivalent rLP2086 group and two (3%) of 80 participants i

250 Bivalent rLP2086 is a recombinant factor H binding prote

251 trains (A22, A56, and B24), more than 50% of bivalent rLP2086 recipients continued to achieve titres

252 After three doses of bivalent rLP2086, protective hSBA titres above the corre

253 INTERPRETATION: After three doses of bivalent rLP2086, protective hSBA titres above the corre

254 up to 4 years after a three-dose schedule of bivalent rLP2086.

255 we describe the preclinical development of a bivalent RSV/HPIV1 vaccine based on a recombinant HPIV1

256 imeric rB/HPIV3 vector expressing RSV F as a bivalent RSV/HPIV3 vaccine and have been evaluating mean

257 nificantly increased F immunogenicity in the bivalent RSV/HPIV3 vaccine.

258 These findings suggest that a bivalent (S. Typhimurium and S. Enteritidis) vaccine wou

259 te chain (N-IC) is one such IDP that forms a bivalent scaffold with multiple dynein light chains incl

260 The bivalent scaffolds presented two sialyl-LacNAc ligands i

261 volume on the ability of the SAC to inhibit bivalent segregation in meiosis I.

262 Bivalent shells possess two highly structured defects, w

263 PII coat, but that maximal export requires a bivalent signal that derives from motifs on both the car

264 We next proposed a bivalent signaling design where the two extremities of o

265 urvival in aRMS, with EphB4 at the crux of a bivalent signaling node that is either mitogenic or proa

266 Polycomb-regulated lincRNAs reside in the bivalent state in embryonic stem cells and many of them

267 tigen of V. cholerae We demonstrate that the bivalent structure of IgG, although not required for bin

268 Electron deficient, bivalent sulfur atoms have two areas of positive electro

269 Our group developed a family of bivalent synbody affinity ligands using a virus-like par

270 The bivalent targeting was accomplished by linking a hapten

271 This revealed a circuit of bivalent TFAP2A, TFAP2C, GATA2, and GATA3 transcription

272 m cohesion was weakened, and the fraction of bivalents that precociously dissociated into univalents

273 Having separated sister kinetochores allowed bivalents to rotate by 90 degrees on the spindle and inc

274 Thus, TRB1 is a bivalent transcriptional modulator that maintains downre

275 trivalent oral poliovirus vaccine (tOPV) to bivalent types 1 and 3 OPV (bOPV) in 2016, inactivated p

276 was replaced worldwide from April, 2016, by bivalent types 1 and 3 oral polio vaccine (bOPV) and one

277 rivalent oral poliovirus vaccine (tOPV) with bivalent types 1 and 3 oral poliovirus vaccine (bOPV) an

278 A bivalent typhoid and paratyphoid vaccine is needed.

279 INTERPRETATION: Bivalent vaccination has led to a startling reduction in

280 (RSV) fusion (F) glycoprotein, to provide a bivalent vaccine against RSV and HPIV1.

281 n added gene has been under development as a bivalent vaccine against RSV and HPIV3.

282 irus suitable for continued development as a bivalent vaccine against two major childhood pathogens.

283 &G recombinant virus is a safe and effective bivalent vaccine candidate and that the expression of bo

284 in (G) genes of AMPV subtype-C (AMPV-C) as a bivalent vaccine candidate using reverse genetics techno

285 In this study, we developed recombinant bivalent vaccine candidates based on recombinant vaccine

286 A bivalent vaccine containing HPV 16 and 18 and a quadriva

287 y, we report on vaccine effectiveness of the bivalent vaccine in these vaccinated women who attended

288 d the frequency of genital lesions, with the bivalent vaccine showing the greatest protection.

289 Importantly, mice receiving the optimized bivalent vaccine were fully protected against lethal pul

290 olysaccharide (LPS) induced by the optimized bivalent vaccine were indistinguishable from those elici

291 njections of placebo or norovirus GI.1/GII.4 bivalent vaccine-like particle (VLP) vaccine with 3-O-de

292 e prophylactic benefits from one dose of the bivalent vaccine.

293 gnificant differences invariably favored the bivalent vaccine.

294 ining TT such as PsA-TT should be considered bivalent vaccines because of their ability to boost teta

295 We constructed novel bivalent vaccines through the recombinant expression of

296 linically in mice, for the delivery of novel bivalent viral-vectored vaccines.

297 is, localization of topoisomerase IIalpha to bivalents was not affected; however, localization of con

298 Bivalent whole-cell oral cholera vaccine effectively pro

299 n was done in Haiti with an oral inactivated bivalent whole-cell vaccine.

300 Our data suggest that H3K27me3 levels at the bivalent Zbtb16/PLZF gene define a threshold enabling pr